Stay updated with breaking news from Pascal Prigent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024Transformative milestone expected towards end
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet...
Genfit has signed an exclusivity agreement for the acquisition of clinical-stage biotechnology firm, Versantis, for $109m (Sfr105m).
GENFIT is set to acquire Versantis, a Swiss biotechnology company focused on addressing the growing unmet medical needs in liver diseases.
Liver disease remains the focus of Genfit, despite a high-profile clinical trial failure in the fatty liver disease NASH. The company is building out its pipeline by acquiring Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a deadly chronic liver disease complication that has no FDA-approved therapies.